Currently out of the existing stock ratings of Paul Choi, 41 are a SELL (16.4%), 89 are a HOLD (35.6%), 120 are a BUY (48%).

Paul Choi

Work Performance Price Targets & Ratings Chart

Analyst Paul Choi, carries an average stock price target met ratio of 61.14% that have a potential upside of 32.99% achieved within 181 days. Previously, Paul Choi worked at GOLDMAN SACHS, BARCLAYS.

Paul Choi’s has documented 492 price targets and ratings displayed on 52 stocks. The coverage was on Healthcare, Pharmaceuticals, Technology sectors.

Most recent stock forecast was given on EWTX, Edgewise Therapeutics at 11-Aug-2026.

Wall Street Analyst Paul Choi

Analyst best performing recommendations are on SBTX (SILVERBACK THERAPEUTICS).
The best stock recommendation documented was for GBT (GLOBAL BLOOD THERAPEUTICS) at 8/4/2022. The price target of $66 was fulfilled within 4 days with a profit of $18.01 (37.53%) receiving and performance score of 93.82.

Average potential price target upside

of $113.17 (26.32%) on FGEN (FIBROGEN).
of $61 (16.14%) on NKTR (NEKTAR THERAPEUTICS).
of $60.01 (56.75%) on ASND (ASCENDIS PHARMA AS).

ALLK Allakos AMRN Amarin PLC AXLA Axcella Health BBIO BridgeBio Pharma ESPR Esperion Therapeutics FGEN FibroGen FREQ Frequency Therapeutics HCM HUTCHMED DRC KNSA Kiniksa Pharmaceuticals Ltd MYOV Myovant Sciences Ltd NBIX Neurocrine Biosciences NKTR Nektar Therapeutics ODT Odonate Therapeutics PBYI Puma Biotechnology PHAT Phathom Pharmaceuticals PMVP Pmv Pharmaceuticals TPTX Turning Point Therapeutics URGN UroGen Pharma Ltd VIE Viela Bio VIR Vir Biotechnology BHVN Biohaven Pharmaceutical Holding Co Ltd NGM NGM Biopharmaceuticals FHTX Foghorn Therapeutics IMMU Immunomedics SBTX Silverback Therapeutics CLVS Clovis Oncology SWTX SpringWorks Therapeutics XLRN Acceleron Pharma GOSS Gossamer Bio AIMT Aimmune Therapeutics GBT Global Blood Therapeutics KNTE Kinnate Biopharma MDCO The Medicines Company MGTA Magenta Therapeutics RDUS Schnitzer Steel Industries ASND Ascendis Pharma AS PTCT PTC Therapeutics CYTK Cytokinetics DVAX Dynavax Technologies RGNX Regenxbio APLT Applied Therapeutics ARVN Arvinas EXEL Exelixis XENE Xenon Pharmaceuticals LNTH Lantheus Holdings ARRY Array Technologies EWTX Edgewise Therapeutics FR First Industrial Realty Trust MD Mednax SLNO Soleno Therapeutics SW Smurfit WestRock plc RPTX Repare Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Jonathan Wolleben (JMP)

Buy

$1.79 (147.93%)

2 years 26 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Please subscribe to see extended stock data

Jennifer Kim (CANTOR FITZGERALD)

Hold

2 years 4 months 2 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

Please subscribe to see extended stock data

Carter Gould (BARCLAYS)

Sell

$-0.21 (-17.36%)

$1.5

2 years 9 months 5 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Please subscribe to see extended stock data

Tim Lugo (WILLIAM BLAIR)

Buy

2 years 10 months 4 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Please subscribe to see extended stock data

Maury Raycroft (JEFFERIES)

Buy

$7.79 (643.80%)

3 years 5 months 11 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Please subscribe to see extended stock data

Show more analysts

Please expand the browser size to see the chart

Which stock is Paul Choi most bullish on?

Potential upside of $11.41 has been obtained for KNSA (KINIKSA PHARMACEUTICALS LTD)

Which stock is Paul Choi most reserved on?

Potential downside of -$1.19 has been obtained for EWTX (EDGEWISE THERAPEUTICS)